<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271501</url>
  </required_header>
  <id_info>
    <org_study_id>CTP008</org_study_id>
    <nct_id>NCT04271501</nct_id>
  </id_info>
  <brief_title>Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions</brief_title>
  <official_title>A Prospective Blinded Randomized Within-Subject Controlled Clinical Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure (MKTP) for Repigmentation of Stable Vitiligo Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avita Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avita Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized within-subject controlled feasibility study to evaluate the clinical&#xD;
      performance of RECELL for repigmentation of stable, depigmented lesions. The trial will&#xD;
      evaluate 50 matched, stable depigmented areas from 10 subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Each subject serves as their own control.</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Repigmentation will be evaluated via measurement of the area repigmented and will be rated by the patient and a Blinded Evaluator (blinded to treatment allocation) using standardized photographs.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Repigmentation</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percent area repigmented for each study area compared to standardized reference photos by a Blinded Evaluator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorization of Repigmentation</measure>
    <time_frame>24 weeks</time_frame>
    <description>Categorization of each study area in terms of ranges of percent repigmentation by a Blinded Evaluator (0-25%, 26-50%, 51-79%, 80-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of treated lesions achieving â‰¥80% or &lt;80% repigmentation as assessed by a Blinded Evaluator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Repigmentation Rating</measure>
    <time_frame>24 weeks</time_frame>
    <description>Ratings of poor, moderate, good, or excellent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinded Evaluator Color Matching</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessment of color matching (0-3: poor, moderate, good, excellent) inclusive of hypopigmentation and hyperpigmentation</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Area without surgical intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melanocyte-Keratinocyte Transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous skin cell suspension prepared by laboratory based melanocyte-keratinocyte transplantation procedure technique applied to a surgically prepared area of depigmentation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RECELL 1:5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regenerative epidermal suspension diluted 1:5 applied to a surgically prepared area of depigmentation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RECELL 1:10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regenerative epidermal suspension diluted 1:10 applied to a surgically prepared area of depigmentation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RECELL 1:20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regenerative epidermal suspension diluted 1:20 applied to a surgically prepared area of depigmentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB)</intervention_name>
    <description>Application of melanocytes (aka melanocyte-keratinocyte transplantation procedure or MKTP) to surgically prepared depigmented areas</description>
    <arm_group_label>Melanocyte-Keratinocyte Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RECELL 1:5 and Ultraviolet Lamp (UVB)</intervention_name>
    <description>Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation</description>
    <arm_group_label>RECELL 1:5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RECELL 1:10 and Ultraviolet Lamp (UVB)</intervention_name>
    <description>Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation</description>
    <arm_group_label>RECELL 1:10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RECELL 1:20 and Ultraviolet Lamp (UVB)</intervention_name>
    <description>Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation</description>
    <arm_group_label>RECELL 1:20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following criteria to be eligible:&#xD;
&#xD;
          1. Focal, segmental or generalized (i.e., nonsegmental) vitiligo documented as stable (no&#xD;
             new lesions nor lesions expanding in size within the preceding 12 months, regardless&#xD;
             of whether the lesions are intended for treatment in this study).&#xD;
&#xD;
          2. The patient has not undergone topical treatment (e.g., steroids) for the study lesion&#xD;
             within the past 60 days.&#xD;
&#xD;
          3. The patient has not undergone phototherapy (e.g., NB-UVB) for the study lesion within&#xD;
             the past 6 months.&#xD;
&#xD;
          4. The patient is a candidate for surgical intervention for treatment of a depigmented&#xD;
             area, defined as: the patient has been compliant but has not satisfactorily responded&#xD;
             to topical therapy and a minimum of 3 months of phototherapy.&#xD;
&#xD;
          5. Five discrete 3cm by 3cm areas are available for treatment within the depigmented&#xD;
             lesion.&#xD;
&#xD;
          6. The 5 study areas must be similarly sun exposed.&#xD;
&#xD;
          7. The extent of leukotrichia must be similar between the two study areas.&#xD;
&#xD;
          8. The patient is &gt; 22 years of age.&#xD;
&#xD;
          9. The patient is willing and able to comply with post-treatment at-home phototherapy and&#xD;
             all follow-up evaluations required by the study protocol.&#xD;
&#xD;
         10. The patient agrees to abstain from any other treatment of the study areas for the&#xD;
             duration of the his/her participation in the study (24 weeks).&#xD;
&#xD;
         11. The patient agrees to abstain from enrollment in any other interventional clinical&#xD;
             trial for the duration of his/her participation in the study (24 weeks).&#xD;
&#xD;
         12. In the opinion of the investigator, the patient and/or guardian must be able to:&#xD;
&#xD;
               1. Understand the full nature and purpose of the study, including possible risks and&#xD;
                  adverse events,&#xD;
&#xD;
               2. Understand instructions, and&#xD;
&#xD;
               3. Provide voluntary written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria are not eligible:&#xD;
&#xD;
          1. The area requiring treatment is not associated with vitiligo.&#xD;
&#xD;
          2. Study areas contain the distal phalanges.&#xD;
&#xD;
          3. The patient in unable to undergo the treatment area preparation.&#xD;
&#xD;
          4. Patients who are pregnant.&#xD;
&#xD;
          5. Patients with universalis vitiligo, depigmented areas over &gt;30% of their body surface&#xD;
             area, or depigmented fingertips.&#xD;
&#xD;
          6. Patient with a history of keloid formation.&#xD;
&#xD;
          7. Patients who have used a tanning salon in the past 60 days.&#xD;
&#xD;
          8. The patient has other concurrent conditions that in the opinion of the investigator&#xD;
             may compromise patient safety or study objectives.&#xD;
&#xD;
          9. Current use of medications (e.g., anticoagulants such as such as heparin or warfarin)&#xD;
             that in the investigator's opinion may compromise patient safety or trial objectives.&#xD;
&#xD;
         10. The patient has a known hypersensitivity to trypsin or compound sodium lactate for&#xD;
             irrigation (Hartmann's) solution.&#xD;
&#xD;
         11. The patient has recent history (within 12 months) of Koebner phenomenon and/or&#xD;
             confetti-like or trichrome lesions.&#xD;
&#xD;
         12. Life expectancy is less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth Kirshner</last_name>
    <phone>661-367-9180</phone>
    <email>ekirshner@avitamedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Carothers</last_name>
    <phone>661-568-1311</phone>
    <email>lcarothers@avitamedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celia Hartigan</last_name>
      <email>Celia.Hartigan@umassmed.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitiligo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

